July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Human Serum Metabolomics Study in Macular Telangiectasia Type 2
Author Affiliations & Notes
  • Sasha Woods
    UCL Institute of Ophthalmology, London, United Kingdom
  • Michael Powner
    UCL Institute of Ophthalmology, London, United Kingdom
  • Senthil Selvam
    UCL Institute of Ophthalmology, London, United Kingdom
  • Kamron Khan
    University of Leeds, Leeds, United Kingdom
  • Robyn H Guymer
    University of Melbourne, Melbourne, Victoria, Australia
  • Jennifer Trombley
    Lowy Medical Research Institute, San Diego, California, United States
  • Catherine Egan
    Moorfields Eye Hospital, London, United Kingdom
  • Martin Friedlander
    Lowy Medical Research Institute, San Diego, California, United States
  • Marcus Fruttiger
    UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships   Sasha Woods, None; Michael Powner, None; Senthil Selvam, None; Kamron Khan, None; Robyn Guymer, None; Jennifer Trombley, None; Catherine Egan, None; Martin Friedlander, None; Marcus Fruttiger, None
  • Footnotes
    Support  The Lowy Medical Research Institute
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3154. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sasha Woods, Michael Powner, Senthil Selvam, Kamron Khan, Robyn H Guymer, Jennifer Trombley, Catherine Egan, Martin Friedlander, Marcus Fruttiger; Human Serum Metabolomics Study in Macular Telangiectasia Type 2. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3154.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Macular telangiectasia (MacTel) type 2 is an uncommon bilateral eye disease causing central vision loss. Retinal alterations begin in a temporal paracentral area, eventually affecting a characteristic oval region around the foveal centre. A recent genome-wide association study (GWAS) identified 5 genetic susceptibility loci for MacTel, 4 of which are implicated in the glycine/serine metabolic pathway. Furthermore, MacTel patients were shown to have reduced glycine/serine levels in their serum. Here we present a global metabolomics analysis of MacTel patients and matched controls.

Methods : 50 patients and 50 independent controls (matched for age, sex, ethnicity and diabetes status) were selected from a number of participating centres. Following overnight fasting, blood samples were collected into serum separator tubes and centrifuged (1200rpm, 10 minutes, 20°C) after 30 minutes. Serum aliquots of 200µl were shipped to Metabolon Inc. in dry ice, where non-targeted mass-spectrometry (MS) analysis was performed using ultrahigh-performance liquid chromatography-tandem MS. To identify biochemicals that differed significantly between patients and controls and to correct for the false discovery rate (FDR), the Benjamin-Hochberg procedure was used.

Results : In total, 1256 metabolites were identified in this study. Principal component analysis (PCA) revealed poor separation of MacTel patients from controls, indicating that the global metabolic profiles of the two groups were similar. 47 metabolites showed differences with p-values <0.05 and a further 25 had p-values ≥0.05 and ≤0.10. Amongst these, glycine and serine had the highest significance levels and were reduced by about 20% in MacTel patients. Further amino acids were also significantly lower in MacTel patients compared to controls, whilst a number of lipids – particularly phosphatidylethanolamines – were significantly higher (by about 20%). Moreover, MacTel patients also show evidence of increased levels of oxidative stress, associated with changes in cysteine/methionine metabolism.

Conclusions : Our data further implicates systemic abnormalities beyond the retinal phenotype in MacTel type 2 and identifies potential new biomarkers for this disease.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.